The Diagnostic Value of Anti-Mullerian Hormone and Follicular Stimulating Hormone in Polycystic Ovary Syndrome Patients

Abstract

Abstract

Objective: To evaluate the anti-mullerian hormone (AMH) and follicular stimulating hormone (FSH) in polycystic ovary syndrome patients (POCS) and their potential as markers of PCOS.

Methods: This was a comparative cross-sectional study carried out on 80 women aged 18-50 years: 40 were healthy women with non-polycystic ovary syndrome serving as control group and 40 were patients with PCOS. Fasting venous blood (6 ml) was collected from each individual in the second day of the menstrual cycle and AMH, FSH, luteinizing hormone (LH), prolactin and estradiol (E2) as well as fasting blood glucose (FBG) and lipid profile were measured.

Results: Serum AMH was significantly (p = 2x10-4) higher in PCOS patients by 3.5-folds with respect to the control group, whereas FSH was significantly (p = 0.01) lower by 36.5%. In contrast, LH, prolactin, estradiol, FBG and the lipid profile were non-significantly different between the two tested groups. Serum AMH was negatively correlated with age (r = - 0.355, p = 0.001) and FSH (r = - 0.454, p = 2x10-6).

Conclusion: This study shows that AMH can be used as a diagnostic and prognostic marker in POCS.